Ilsung Pharm (KO:003120) — Market Cap & Net Worth
Market Cap & Net Worth: Ilsung Pharm (003120)
Ilsung Pharm (KO:003120) has a market capitalization of $105.81 Million (₩156.13 Billion) as of September 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19084 globally and #923 in its home market, demonstrating a 4.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ilsung Pharm's stock price ₩21800.00 by its total outstanding shares 7162047 (7.16 Million). Also see 003120 current and non-current assets for a full breakdown of the balance sheet.
Ilsung Pharm Market Cap History: 2015 to 2026
Ilsung Pharm's market capitalization history from 2015 to 2026. Data shows growth from $76.65 Million to $105.81 Million (3.93% CAGR). Also see Ilsung Pharm cash flow conversion for how efficiently the company converts equity into cash flow.
Ilsung Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ilsung Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Ilsung Pharm stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Ilsung Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.09x
Ilsung Pharm's market cap is 0.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $82.86 Million | $67.46 Billion | $3.02 Billion | 0.00x | 0.03x |
| 2017 | $90.77 Million | $67.04 Billion | $2.63 Billion | 0.00x | 0.03x |
| 2018 | $65.27 Million | $61.65 Billion | $2.95 Billion | 0.00x | 0.02x |
| 2019 | $56.57 Million | $48.41 Billion | $6.72 Billion | 0.00x | 0.01x |
| 2020 | $57.51 Million | $40.60 Billion | $3.22 Billion | 0.00x | 0.02x |
| 2021 | $51.84 Million | $42.09 Billion | -$1.37 Billion | 0.00x | N/A |
| 2022 | $77.42 Million | $61.25 Billion | $105.24 Billion | 0.00x | 0.00x |
| 2023 | $114.79 Million | $78.05 Billion | -$20.94 Billion | 0.00x | N/A |
| 2024 | $75.23 Million | $69.02 Billion | $13.09 Billion | 0.00x | 0.01x |
| 2025 | $105.81 Million | $64.29 Billion | $1.17 Billion | 0.00x | 0.09x |
Competitor Companies of 003120 by Market Capitalization
Companies near Ilsung Pharm in the global market cap rankings as of September 18, 2026. Review how tangible is Ilsung Pharm's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ilsung Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Ilsung Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Ilsung Pharm's market cap moved from $76.65 Million to $ 105.81 Million, with a yearly change of 3.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩105.81 Million | 0.00% |
| 2025 | ₩105.81 Million | +40.65% |
| 2024 | ₩75.23 Million | -34.46% |
| 2023 | ₩114.79 Million | +48.27% |
| 2022 | ₩77.42 Million | +49.34% |
| 2021 | ₩51.84 Million | -9.85% |
| 2020 | ₩57.51 Million | +1.66% |
| 2019 | ₩56.57 Million | -13.33% |
| 2018 | ₩65.27 Million | -28.10% |
| 2017 | ₩90.77 Million | +9.55% |
| 2016 | ₩82.86 Million | +8.09% |
| 2015 | ₩76.65 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Ilsung Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $105.81 Million USD |
| MoneyControl | $105.81 Million USD |
| MarketWatch | $105.81 Million USD |
| marketcap.company | $105.81 Million USD |
| Reuters | $105.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more